We are live on ! Find out more
BIOTU

Biotech Acquisition Company Unit

Delisted

BIOTU was delisted on the 2nd of February, 2023.

15 hedge funds and large institutions have $5.18M invested in Biotech Acquisition Company Unit in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% less funds holding

Funds holding: 3415 (-19)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

89% less capital invested

Capital invested by funds: $45.2M → $5.18M (-$40M)

90% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 21

Holders
15
Holders Change
-19
Holders Change %
-55.88%
% of All Funds
0.23%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
1
Reduced
3
Closed
21
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
HF
1
HRT Financial
New York
$900K
SMA
2
Sage Mountain Advisors
Georgia
$510K
COPPSERS
3
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$508K
WCMNY
4
Westchester Capital Management (New York)
New York
$501K
WC
5
Wealthspring Capital
New York
$461K -$72.9K -7,201 -14%
Millennium Management
6
Millennium Management
New York
$455K
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$424K
SIA
8
Schechter Investment Advisors
Michigan
$346K +$349K +34,525 New
BCM
9
BCK Capital Management
Connecticut
$275K +$4.21K +416 +2%
Walleye Capital
10
Walleye Capital
New York
$249K -$965K -95,403 -80%
LCM
11
Landscape Capital Management
New Jersey
$223K
OCAM
12
Owl Creek Asset Management
New York
$202K
Morgan Stanley
13
Morgan Stanley
New York
$85K
SIA
14
SkyView Investment Advisors
New Jersey
$32K +$32.2K +3,183 New
UBS Group
15
UBS Group
Switzerland
$5K -$810 -80 -14%
AC
16
Aristeia Capital
Connecticut
-$11.5M -1,149,010 Closed
HIM
17
HGC Investment Management
Ontario, Canada
-$11.1M -1,101,900 Closed
MF
18
Magnetar Financial
Illinois
-$4.45M -442,393 Closed
GCL
19
Glazer Capital LLC
New York
-$3.11M -309,501 Closed
CCM
20
Context Capital Management
California
-$1.95M -194,400 Closed
JP Morgan Chase
21
JP Morgan Chase
New York
-$1.43M -142,720 Closed
CIM
22
Cowen Investment Management
New York
-$1.25K -125,000 Closed
SCM
23
Shaolin Capital Management
Florida
-$1.07M -106,888 Closed
CCFM
24
Cohen & Co Financial Management
New York
-$1M -100,000 Closed
HP
25
Hound Partners
New York
-$999K -99,505 Closed

BIOTU Hedge Fund Activity: Q4 2021 in Review

15 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Unit (BIOTU) for Q4 2021, worth a combined $5.18M — down 89% from $45.2M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of BIOTU and 2 opened new positions — a net loss of 19 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was SkyView Investment Advisors, opening a new position worth an estimated $32.2K. The largest seller was Aristeia Capital, exiting entirely with an estimated $11.5M sold.

  • 15 institutional investors held Biotech Acquisition Company Unit (BIOTU) as of Q4 2021, down from 34 in Q3 2021.
  • Funds reported $5.18M of Biotech Acquisition Company Unit stock for Q4 2021, down 89% quarter-over-quarter.
  • 2 funds opened new Biotech Acquisition Company Unit positions in Q4 2021 and 21 closed out, a net change of -19 holders.
  • The largest Biotech Acquisition Company Unit buyer in Q4 2021 was SkyView Investment Advisors, an estimated $32.2K added.
  • The largest Biotech Acquisition Company Unit seller in Q4 2021 was Aristeia Capital, an estimated $11.5M sold.

Based on aggregated 13F filings for Q4 2021.